Calix, Inc. filings document the regulatory record of an operating technology company that sells cloud, platform, and managed-service offerings for communications service providers. Its 8-K reports cover quarterly financial results distributed through stockholder letters, including non-GAAP measures such as gross margin, operating expenses, net income, diluted earnings per share, and free cash flow.
Other Calix filings address common-stock repurchase authorizations, board and officer matters, and annual meeting governance. Proxy materials disclose director elections, advisory executive compensation votes, equity and stock purchase plan matters, board oversight, and related stockholder voting items.
Calix, Inc. (CALX) reported an insider transaction by its Chief Product Officer. On 11/04/2025, the officer exercised stock options for 50,000 shares of common stock at $7 per share (code M), then sold 50,000 shares at a weighted average price of $65.3371 (code S). Following these transactions, the filing shows 0 shares of common stock directly owned and 0 derivative securities remaining. The sales occurred in multiple trades between $65.025 and $65.685, with full trade details available upon request. The option had been fully vested and exercisable since August 1, 2022.
Calix (CALX) director and 10% owner Carl Russo reported insider trades.
On 11/04/2025, he sold common stock under a Rule 10b5‑1 plan adopted April 25, 2025: 395,000 shares at $64, 12,035 at $65.1088 (weighted average), 12,845 at $66.0028 (weighted average), and 120 at $66.47. On 11/06/2025, he exercised 200,000 options at $12.63, with 3,953,070 shares beneficially owned directly afterward. Certain shares are held indirectly via The Crescentico Trust and Equanimous Investments.
CALX filed a Form 144 notice for proposed sales of common stock, listing 395,000 shares (via J.P. Morgan Securities) and 25,000 shares (via Wells Fargo Clearing Services). The filing shows aggregate market values of $25,280,000 and $1,639,367, respectively, with an approximate sale date of 11/04/2025 on the NYSE.
The notice also lists how the seller acquired the shares over time, including purchases on 12/21/1999 (102,704 shares), 06/23/2000 (75,476), 02/23/2001 (13,658), 06/12/2002 (203,162), and a stock option exercise on 01/30/2023 (25,000). Shares outstanding were 66,276,473; this is a baseline figure, not the amount being sold.
Calix (CALX) received a Form 144 notice indicating a holder’s intent to sell 50,000 shares of common stock. The filing lists an aggregate market value of $3,266,850.00 and an approximate sale date of 11/04/2025.
The shares were acquired via a stock option exercise on 11/04/2025 with cash payment. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE. As context, 66,276,473 shares were outstanding.
Calix (CALX) reported insider transactions by President & CEO Michael Weening. He exercised 274,000 stock options at $7.84 and sold 274,000 shares pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
On 10/30/2025, he exercised 200,000 shares, then sold 150,000 shares at a weighted average $64.628 (range $64.55–$65.00) and 50,000 shares at $67.5456 (range $67.35–$67.93). On 11/03/2025, he exercised 74,000 shares and sold 74,000 shares at $67.4203 (range $66.245–$69.450). Shares beneficially owned were 16,117 after the reported transactions. The options exercised were fully vested as of November 27, 2023 and expire on November 27, 2029.
Calix (CALX) filed a Form 144 indicating a proposed sale of 74,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $4,989,102.20. The filing lists an approximate sale date of 11/03/2025 on the NYSE. The shares were acquired the same day via a stock option exercise for cash.
Shares outstanding were 66,276,473; this is a baseline figure, not the amount being sold. Recent insider sales disclosed in the notice over the past three months include 200,000 shares on 10/30/2025 for $13,071,475.00 and 157,990 shares on 09/10/2025 for $9,803,370.00. The filer represents they do not know of undisclosed material adverse information at the time of the notice.
Calix, Inc. reported insider transactions by CFO Cory Sindelar on a Form 4. He exercised stock options at $5.05 for 10,000 shares on October 30, 2025 and sold 10,000 shares at $65 the same day. He repeated this on October 31, 2025, exercising options at $5.05 for 10,000 shares and selling 10,000 shares at $70.
Following the reported transactions, he held 76,555 shares of common stock directly. The option awards had an exercise price of $5.05, were fully vested as of October 1, 2021, and carry an expiration date of October 1, 2027. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2025.
Calix, Inc. (CALX) filed a Form 144 indicating that Cory J Sindelar plans to sell 10,000 shares of common stock with an aggregate market value of $700,000. The proposed sale is listed for 10/31/2025 on the NYSE through Morgan Stanley Smith Barney LLC.
The filing notes the shares were acquired via a stock option exercise on 10/31/2025 with cash payment. Recent activity disclosed includes sales by the same seller of 10,000 shares for $650,000 on 10/30/2025 and 10,000 shares for $600,000 on 08/28/2025.
CALX filed a Form 144 notice for a proposed sale of 200,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $13,071,475. The approximate sale date is 10/30/2025 on the NYSE.
The shares were acquired via a stock option exercise on 10/30/2025 for cash. The filing lists 66,276,473 shares outstanding for the issuer as context.
Recent activity disclosed includes sales over the past three months by Michael Weening: 74,000 shares for $4,218,000 on 08/04/2025, 126,000 for $7,560,000 on 08/28/2025, 24,000 for $1,440,000 on 09/04/2025, 157,990 for $9,803,370 on 09/10/2025, and 18,010 for $1,134,630 on 09/11/2025.
Calix (CALX) received a Form 144 notice for a proposed sale of 10,000 shares of common stock with an aggregate market value of $650,000. The shares are planned to be sold on or about 10/30/2025 through Morgan Stanley Smith Barney LLC on the NYSE.
The securities were acquired on 10/30/2025 via a stock option exercise for 10,000 shares, paid in cash. In the past three months, the seller reported a sale of 10,000 shares on 08/28/2025 for gross proceeds of $600,000. The filing lists 65,303,995 shares outstanding for the issuer.